Loading
Life sciences · Journal article
Endocrinology and Metabolism · August 6, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study of 613 patients undergoing pancreaticoduodenectomy without baseline diabetes found that sarcopenic obesity independently predicted new-onset diabetes at 1 year (OR 3.65; 95% CI 1.09–14.43) and was associated with persistent insulin resistance. The 1-year analysis is underpowered and limited to 143 patients, limiting generalizability.
Retrospective cohort study. Patients without preexisting diabetes who underwent pancreaticoduodenectomy between 2015 and 2023.. Intervention: Pancreaticoduodenectomy (PD). Compared with: Sarcopenic obesity status (defined as visceral fat area/skeletal muscle index >2.5 m²) and other clinical covariates. n = 613.
At 3 months post-PD, 8.2% (50/613) of patients developed new-onset diabetes; hypertension (OR 2.45), elevated preoperative HbA1c (OR 2.31), and adjuvant chemotherapy (OR 3.15) were independent predictors. At 1 year, 9.8% (14/143) developed diabetes, with sarcopenic obesity as the sole independent predictor (OR 3.65; 95% CI 1.09 to 14.43). Patients with sarcopenic obesity had significantly higher postoperative hemoglobin A1c, C-peptide, and insulin resistance at 1 year than those without.
No p-values reported for 1-year sarcopenic obesity analysis; no data on absolute risk difference or number needed to harm.
Clinicians should consider preoperative sarcopenic obesity assessment in patients undergoing pancreaticoduodenectomy, as it strongly predicts postoperative insulin resistance and new-onset diabetes at 1 year. Targeted metabolic interventions for this high-risk population may be warranted, pending validation in prospective studies.
Retrospective cohort study with clear methodology and pre-specified outcome showing sarcopenic obesity as an independent predictor of new-onset diabetes after pancreaticoduodenectomy, but limited by single-centre design, non-randomized conduct, and modest sample size for the 1-year analysis.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider preoperative sarcopenic obesity assessment in patients undergoing pancreaticoduodenectomy, as it strongly predicts postoperative insulin resistance and new-onset diabetes at 1 year. Targeted metabolic interventions for this high-risk population may be warranted, pending validation in prospective studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Sarcopenic obesity, characterized by reduced skeletal muscle mass accompanied by excessive visceral fat accumulation, has recently gained attention as a crucial determinant of metabolic dysfunction. Although pancreaticoduodenectomy (PD) is increasingly performed with improved surgical outcomes, the incidence and risk factors for new-onset diabetes after PD remain incompletely understood. This study investigated the impact of sarcopenic obesity on postoperative glucose metabolism. Methods: A total of 613 patients without preexisting diabetes who underwent PD between 2015 and 2023 were retrospectively analyzed. Diabetes status was evaluated preoperatively and at 3 months postoperatively (Cohort 1), and a subset of 143 patients was reassessed at 1 year (Cohort 2). Sarcopenic obesity was defined as a visceral fat area/skeletal muscle index >2.5 m2. Diabetes was defined according to the American Diabetes Association criteria. Results: At 3 months after surgery, 8.2% (50/613) of patients developed diabetes. Independent predictors included hypertension (odds ratio [OR], 2.45), elevated preoperative hemoglobin A1c (OR, 2.31), and receipt of adjuvant chemotherapy (OR, 3.15). At 1 year, 9.8% (14/143) developed diabetes, with sarcopenic obesity emerging as the sole independent predictor (OR, 3.65; 95% confidence interval, 1.09 to 14.43). Additionally, patients with sarcopenic obesity had significantly higher levels of hemoglobin A1c, Cpeptide, and insulin resistance 1 year after surgery than those without sarcopenic obesity. Conclusion: Sarcopenic obesity was associated with persistent postoperative insulin resistance. These findings suggest that sarcopenic obesity constitutes a key determinant of new-onset diabetes after PD and highlight the need for preoperative assessment and targeted metabolic interventions in this high-risk population.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.